Media stories about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.2553820845101 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Anika Therapeutics (ANIK) opened at $59.03 on Monday. The company has a market capitalization of $865.48, a price-to-earnings ratio of 27.71, a price-to-earnings-growth ratio of 3.58 and a beta of 1.44. Anika Therapeutics has a 12-month low of $41.64 and a 12-month high of $60.29.
Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.05. The company had revenue of $27.18 million for the quarter, compared to the consensus estimate of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. Anika Therapeutics’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. equities analysts predict that Anika Therapeutics will post 1.9 earnings per share for the current year.
In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.57% of the company’s stock.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.